ClinicalTrials.gg
RecruitingNCT05650411ULTIMATE-LMUpdated May 4, 2026

Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)

An interventional study of LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). and P2Y12 inhibitor-based SAPT after short DAPT in Left Main Coronary Artery Stenosis, sponsored by IGLESIAS Juan Fernando. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by IGLESIAS Juan Fernando · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
828
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.

Planned enrollment
42nd of 125
828 · median 296
Started
2026
with 6 others
No phase
78 of 177
14 open now
Primary completion
2028-05
later than 25 of 40 live
Registered
156th of 177
by date

Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 42nd largest by planned enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2026, is one of 78 with no phase, reaches primary completion later than 25 of the 40 other live ones, and was the 156th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Coronary Artery Disease with a site in Switzerland, or all of them as a file.
02

Study summary

The management of patients with unprotected left main coronary artery (LMCA) disease undergoing percutaneous coronary intervention (PCI) in contemporary interventional cardiology practice remains matter of intense debate. Particularly, the combination of the optimal drug-eluting stent (DES) selection and antiplatelet regimen for patients who require LMCA PCI remains undetermined.

Newer-generation drug-eluting stents with ultrathin-strut metallic platforms have been shown to reduce the risk of target lesion failure compared with thicker-strut drug-eluting stents among all-comer patients undergoing PCI, a difference mainly driven by a lower risk of ischemia-driven target lesion revascularization. In the TALENT prospective, single-blind, multicenter, randomized controlled trial that included 1'435 all-comer patients undergoing PCI, the Supraflex ultrathin-strut biodegradable polymer sirolimus-eluting stent was found non-inferior to the Xience® thin-strut permanent polymer everolimus-eluting stent (Abbott Vascular, USA) with regards to the device-oriented composite clinical endpoint (DoCE), a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization, at 12 months of follow-up. However, the TALENT trial included only 31 (1.5%) lesions located in the left main coronary artery. In the COMPARE 60/80 HBR investigator-initiated, multicenter, prospective randomized trial which included a total of 732 patients at high-bleeding risk undergoing PCI with the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent or the Ultimaster Tansei (Terumo Corp., Tokyo, Japan), the rates of the primary endpoint of the net adverse clinical endpoint, defined as a composite of cardiac death, myocardial infarction, target vessel revascularization, stroke, or BARC 3 or 5 major bleeding events at 12 months were similar in the Supraflex Cruz and the Ultimaster Tansei groups, meeting the prespecified criterion for non-inferiority of the Supraflex Cruz DES compared to the Ultimaster Tansei DES. The safety and efficacy of the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent combined with potent P2Y12 inhibitor aspirin-free SAPT among all-comer patients undergoing PCI for complex coronary lesions, such as patients with LMCA stenosis, have however not been investigated to date.

Recent evidence from a large-scale meta-analysis of several randomized clinical trials including >32'000 patients indicated that 1-3 months of DAPT followed by P2Y12 inhibitor single antiplatelet therapy (SAPT) after second-generation DES implantation was associated with lower risk for major bleeding and similar risk for adverse ischemic outcomes compared with conventional DAPT. These findings suggest that P2Y12 inhibitor SAPT following a short DAPT course (1-3 months) may represent a valuable treatment option for patients undergoing PCI with newer-generation DES compared to standard conventional 12 months DAPT, but this strategy has never been investigated in dedicated randomized clinical trials focused on patients at highest-risk for ischaemic events, such as patients undergoing LMCA PCI.

The ULTIMATE-LM randomized trial aims at filling this current gap of knowledge, which may have large impact on clinical practice and international guidelines. ULTIMATE-LM will be the first randomized clinical trial to investigate the safety and efficacy of a novel ultrathin-strut biodegradable polymer drug-eluting stent (Supraflex Cruz, Sahajanand Medical Technologies Ltd., Surat, India)) combined with P2Y12 inhibitor-based single antiplatelet therapy among patients undergoing PCI for LMCA disease.

Read the detailed description
  1. Myocardial revascularization for left main coronary artery disease

    Significant left main coronary artery disease (LMCA) is observed in 5-7% of patients undergoing coronary angiography. Coronary revascularization for patients with LMCA disease with stenosis >50% and documented ischemia or FFR ≤0.80 for diameter stenosis \<90%, is recommended with a class of recommendation I and level of evidence (LOE) A by the 2018 European Society of Cardiology (ESC) guidelines for myocardial revascularization. However, the optimal management of patients with LMCA disease requiring myocardial revascularization in contemporary clinical practice remains matter of debate.

  2. Coronary artery bypass grafting vs. percutaneous coronary intervention for left main coronary artery disease

    The available evidence from randomized controlled trials (RCTs) and meta-analyses comparing coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) using drug-eluting stents (DESs) among patients with LMCA suggests equivalent results for the safety composite of death, myocardial infarction (MI), and stroke up to 5 years of follow-up. A significant interaction with time is notable, providing early benefit for PCI in terms of MI and peri-interventional stroke, which is subsequently offset by a higher risk of spontaneous MI during long-term follow-up. The need for repeat revascularization is higher with PCI than with CABG. The largest RCT among patients with LMCA disease so far performed, EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), compared CABG with PCI using new-generation DESs among 1,905 patients with significant LMCA. At 3 years of follow-up, the primary endpoint of death, stroke, or MI occurred with similar frequency in the CABG and PCI group (14.7% vs. 15.4%; HR 1.00, 95% CI 0.79-1.26, p=0.98). The pre-planned landmark analysis from 30 days to 3 years showed a significant difference for the primary endpoint in favour of CABG (7.9% vs. 11.5%, p=0.02). The NOBLE (Nordic-Baltic-British Left Main Revascularization Study) randomized trial compared CABG with PCI using new-generation biolimus-eluting stents among 1,201 patients with significant LM disease (mean SYNTAX score of 23). At a median follow-up of 3.1 years, the primary endpoint of death, non-procedural MI, stroke, and repeat revascularization occurred more frequently in the PCI than the CABG group (29% vs. 19%; HR 1.48, 95% CI 1.11-1.96, p=0.007). A recent collaborative individual patient data pooled analysis of RCTs including 11,518 patients reviewed the currently available evidence from RCTs comparing CABG with PCI for LMCA or multivessel disease. The primary outcome was all-cause mortality. In the overall cohort, CABG was associated with a significant survival benefit during a mean follow-up of 3.8±1.4 years (5-year all-cause mortality 11.2% after PCI vs. 9.2% after CABG; HR 1.20, 95% CI 1.06-1.37, p=0.0038). There was a linear trend for HRs of death increasing with increasing SYNTAX terciles (p=0.0011 for trend). However, among 4,478 patients with LMCA, those randomly assigned to CABG or PCI with a mean follow-up of 3.4±1.4 years reported similar risks for the primary outcome all-cause mortality (PCI, 10.7% vs. CABG, 10.5%; HR 1.07, 95% CI 0.87-1.33, p=0.52) at 5 years. There were no significant differences in mortality between PCI and CABG in subgroup analyses according to SYNTAX scores. Nevertheless, in patients with a high SYNTAX score, a trend towards better survival was noted with CABG. The proportion of patients with a high SYNTAX score was limited in view of the inclusion criteria of the respective studies. Current evidence indicates that PCI is an appropriate alternative to CABG in LMCA and low-to-intermediate anatomical complexity. Among patients with LMCA and low anatomical complexity, there is evidence that the outcomes with respect to major clinical endpoints are similar for PCI and CABG, resulting in a class I recommendation. Among patients with LMCA and high anatomical complexity, the number of patients studied in RCTs is low due to exclusion criteria; the risk estimates and cIs are imprecise but suggest a trend towards better survival with CABG. Therefore, PCI in this setting cannot be endorsed as reflected by a class III recommendation. For PCI in LMCA with intermediate anatomical complexity, the previous class iIa recommendation was maintained in view of the incomplete 5-year follow-up of the two largest RCTs in this setting.

  3. Percutaneous coronary intervention with drug-eluting stents for left main coronary artery disease

    The optimal DES therapy for patients with significant LMCA disease undergoing percutaneous coronary intervention (PCI) in contemporary practice remains undetermined. In the Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions (ISAR-LEFT MAIN-2) (n=650) trial, the cumulative incidence of the primary endpoint, a composite of all-cause death, myocardial infarction, or target lesion revascularization was 17.5% in the thin-strut durable polymer zotarolimus-eluting stent group (Resolute, Medtronic, USA) and 14.3% in the thin-strut biocompatible durable polymer everolimus-eluting stent group (Xience®, Abbott Vascular, USA) (relative risk 1.26; 95% CI]: 0.85 to 1.85; p=0.25) at 12 months. In the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial, the rates of the primary composite endpoint of all-cause death, stroke, or MI, occurred similarly in patients undergoing PCI with the newer-generation thin-strut durable polymer everolimus-eluting stent (Xience®) and coronary artery bypass graft surgery (CABG) (22.0% vs. 19.2%, p=0.13) at 5 years. In the Nordic-Baltic-British left main revascularisation (NOBLE) trial, the rates of the primary composite endpoint of all-cause death, non-procedural MI, any repeat coronary revascularization, and stroke, was 29% in patients undergoing PCI with a thick-strut biodegradable polymer biolimus-eluting stent (Biomatrix Flex®, Biosensors, Switzerland) versus 19% in patients undergoing CABG (HR 1.48, 95% CI 1.11-1.96, CABG significantly better than PCI, p=0.0066) at 5 years. In the Improved Drug Eluting stent for All-comers Left Main (IDEAL-LM) randomized clinical trial, the rate of the primary endpoint, a composite of all-cause death, MI, or clinically indicated target vessel revascularization at 2 years did not differ between patients undergoing PCI with a biodegradable polymer everolimus-eluting stent (Synergy®, Boston Scientific, USA) combined with 4-month Dual Antiplatelet Therapy (DAPT) (14.6%) and those undergoing PCI with a durable polymer everolimus-eluting stent (Xience®, Abbott Vascular, USA) combined with 12-month DAPT (11.4%) (p=0.17). Newer-generation thin-strut polymer-free drug-coated stents have the potential to further mitigate chronic inflammation and promote faster re-endothelialisation. No dedicated randomized clinical trial to date has evaluated the safety and efficacy of newest-generation polymer-free drug-coated stents for PCI in patients with LMCA disease.

  4. Antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease

    The 2018 ESC guidelines on myocardial revascularization recommend at least 6 (chronic coronary syndrome) and 12 (acute coronary syndrome) months of DAPT after PCI with newer-generation DES among patients with unprotected LMCA stenosis. However, a recent meta-analysis of five large-scale randomized clinical trials including a total of 32'145 patients, of whom 972 (3%) patients were treated for LMCA disease, indicated that 1-3 months of DAPT followed by P2Y12 inhibitor single antiplatelet therapy (SAPT) after second-generation DES implantation in patients with chronic and acute coronary syndromes was associated with lower risk for major bleeding (random-effects model: HR 0.63, 95% 0.45-0.86) and similar risk for stent thrombosis (random-effects model: HR 1.19, 95% CI 0.86-1.65), all-cause death (random-effects model: HR 0.85, 95% CI 0.70-1.03), MI (random-effects model: HR 1.05, 95% CI 0.89-1.23), and stroke (random-effects model: HR 1.08, 95% CI 0.68-1.74) compared with conventional DAPT. These findings suggest that a potent P2Y12 inhibitor-based SAPT following a short DAPT course (1-3 months) may represent a preferable treatment option, which is associated with similar ischemic, but lower bleeding risk, for patients undergoing PCI with newer-generation DES compared to standard conventional 12 months DAPT. However, the safety and efficacy of a potent P2Y12 receptor inhibitor-based aspirin-free SAPT after complex PCI, such as PCI for LMCA disease, has not been investigated to date.

  5. Newer-generation ultrathin-strut drug-eluting stents for percutaneous coronary intervention

Newer-generation drug-eluting stents with ultrathin-strut metallic platforms have been shown to reduce the risk of target lesion failure compared with thicker-strut drug-eluting stents among all-comer patients undergoing PCI, a difference mainly driven by a lower risk of ischemia-driven target lesion revascularization. Supraflex Cruz (Sahajanand Medical Technologies Ltd., Surat, India) is a novel newer-generation drug-eluting stent consisting of an L-605 cobalt-chromium alloy metallic stent platform with ultrathin struts (60 μm) across all stent diameters, highly flexible S-link connectors, and a biodegradable polymeric matrix coating (poly L-lactide, 50:50 mixture poly D,L-lactide-co-glycolide and polyvinyl pyrrolidone) eluting sirolimus at a concentration of 1.4 μg/mm2 which is coated on the conformal surface of the stent together with the polymeric matrix. The average thickness of coating ranges from 4 to 5 μm. The drug is 70% released within 7 days, and the remainder is released over a period of 48 days. The polymer gradually degrades over 9-12 months. The proprietary 'LDZ' link design improves stent flexibility, transmits push force with higher efficiency, improves overall radial strength, and resists longitudinal compression. The open-cell design allows for better flexibility and facilitates side branch access. In addition, the 4.0 and 4.5 mm 8-crown stent platforms which allow for an overexpansion capacity up to 5.5 mm facilitates the treatment of patients with large coronary vessels, such as those undergoing LM PCI. In the TALENT prospective, single-blind, multicenter, randomized controlled trial that included 1'435 all-comer patients undergoing PCI, the Supraflex ultrathin-strut biodegradable polymer sirolimus-eluting stent was found non-inferior to the Xience® thin-strut permanent polymer everolimus-eluting stent (Abbott Vascular, USA) with regards to the device-oriented composite clinical endpoint (DoCE), a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization, at 12 months of follow-up. At 3 years, DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (p=0.406). There were no significant between-group differences in rates of cardiac death, target vessel myocardial infarction or clinically indicated target lesion revascularization. The rates of definite or probable stent thrombosis were low and similar between groups (1.1% vs 1.4%; p=0.640). However, the TALENT trial included only 31 (1.5%) lesions located in the left main coronary artery and randomized evidence regarding the safety and efficacy of the Supraflex ultrathin-strut biodegradable polymer sirolimus-eluting stent for PCI in patients with significant LMCA disease remains therefore limited. The TAXCO study investigated the OCT-derived neointimal coverage of the Supraflex Cruz ultrathin-strut biodegradable polymer DES showing that 97.6% of the device struts are endothelialized at 6 months after PCI, which is comparable to the neointimal coverage of the Xience thin-strut everolimus-eluting stent. Equally, no significant difference was found with respect to 6months uncovered and malapposed struts between the 2 devices. Similarly, the SiBi study evaluated the early (4 to 6 weeks) OCT-derived neointimal coverage of the Supraflex Cruz ultrathin-strut biodegradable polymer DES demonstrating an excellent healing profile with a mean of 91.26% strut coverage at 35.3 ± 5 days after the index PCI. Taken together these results indicate an appropriate balance between neointimal thickness and amount of strut coverage that may facilitate short DAPT durations. Particularly, the use of thin strut and ultrathin strut stents may lead to a favorable trade-off in bleeding and ischemic events in patients with high-bleeding risk. In the COMPARE 60/80 HBR investigator-initiated, multicenter, prospective randomized trial which included a total of 732 patients at high-bleeding risk undergoing PCI with the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent or the Ultimaster Tansei (Terumo Corp., Tokyo, Japan), the rates of the primary endpoint of the net adverse clinical endpoint, defined as a composite of cardiac death, myocardial infarction, target vessel revascularization, stroke, or BARC 3 or 5 major bleeding events at 12 months were 15.4% in the Supraflex Cruz group and 17.1% in the Ultimaster Tansei group, meeting the prespecified criterion for non-inferiority of the Supraflex Cruz DES compared to the Ultimaster Tansei DES (p=0.02). The median DAPT duration was 30 (0-181) days. Importantly, a lower rate of target lesion revascularization was observed in the Supraflex Cruz group in comparison to the Ultimaster Tansei group (2.7% vs. 5.3%, p=0.078). Additionally, most other cardiac endpoints showed numerically lower values in the Supraflex Cruz group when compared to the Ultimaster Tansei group. The safety and efficacy of the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India) combined with potent P2Y12 inhibitor aspirin-free SAPT among all-comer patients undergoing PCI for complex coronary lesions, such as patients with LMCA stenosis, have however not been investigated to date.

03

Conditions studied

  • Left Main Coronary Artery Stenosis

Keywords

  • P2Y12 inhibitor-based single antiplatelet therapy
  • Dual antiplatelet therapy
  • Left main coronary artery disease
  • Percutaneous coronary intervention
  • Ultrathin-strut
  • Drug-eluting stent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Patient with chronic or acute coronary syndrome (unstable angina, or non-ST-elevation acute coronary syndrome).
  • Subject with significant unprotected (ostial, mid-shaft, or distal) LMCA stenosis who underwent successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India) according to current ESC guidelines on myocardial revascularization and/or local Heart Team decision.
  • Subject willing to participate and able to understand, read and sign the document before the planned procedure.

Exclusion criteria

Exclusion Criteria:

  • to PCI and/or DES implantation.
  • Inability to adhere to DAPT for at least 6 months.
  • Patient already on DAPT.
  • Patients on oral anticoagulation.
  • Previous coronary artery bypass surgery.
  • LMCA in-stent restenosis or stent thrombosis.
  • Recent ST-elevation myocardial infarction \<5 days prior to randomization.
  • Cardiogenic shock/hemodynamic instability at the time of intervention and/or need for mechanical/pharmacologic hemodynamic support.
  • Participation or planned participation in another clinical trial, except for observational registries.
  • \<1 year.
  • Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
828 participants (estimated)

Study arms

  • Experimental
    P2Y12 inhibitor-based single antiplatelet therapy after a short DAPT strategy arm

    Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). P2Y12 inhibitor SAPT with any of the commercially available oral P2Y12 inhibitors (ticagrelor, or prasugrel 10 mg) after a short DAPT course during 2 years after the index LMCA procedure. At the discretion of the investigator, aspirin will be discontinued after LMCA PCI, or continued during the hospital stay. In all cases, aspirin will be discontinued at latest at hospital discharge.

    Device: LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). · Drug: P2Y12 inhibitor-based SAPT after short DAPT

  • Active comparator
    Conventional DAPT strategy arm

    Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). DAPT combining aspirin and any of the commercially available oral P2Y12 receptor inhibitors (clopidogrel, ticagrelor, or prasugrel) during 6 or 12 months followed by aspirin-based SAPT. In patients with index ACS presentation and who have tolerated DAPT for 12 months without bleeding complications, a prolonged DAPT course with aspirin and ticagrelor 60 mg bd (clopidogrel or prasugrel allowed, if patient not eligible for treatment with ticagrelor) beyond 12 months may be considered in those patients with high thrombotic risk and without an increased risk for major or life-threatening bleeding, and those with moderately elevated thrombotic risk.

    Device: LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). · Drug: Conventional DAPT

Interventions

  • DeviceLMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).

    Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).

  • DrugP2Y12 inhibitor-based SAPT after short DAPT

    Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.

  • DrugConventional DAPT

    6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.

06

What researchers measure

Primary outcomes

  1. Patient-oriented composite endpoint (POCE)

    Composite of all-cause death, any non-fatal myocardial infarction, or any revascularization (PCI, or CABG)

    Time frame: 2 years

Secondary outcomes

  1. Net adverse clinical and major adverse cardiac (NACE)

    Composite of all-cause death, any non-fatal myocardial infarction, any revascularization (PCI, or CABG), or Bleeding Academic Research Consortium (BARC)19 3 or 5 major bleeding

    Time frame: 2 years

  2. Device-oriented composite endpoint (DOCE)

    Composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization (PCI, or CABG)

    Time frame: 2 years

  3. All-cause death

    Cardiac and non-cardiac death

    Time frame: 2 years

  4. Any non-fatal myocardial infarction

    Periprocedural or spontaneous, target vessel-related, and non-target vessel-related myocardial infarction

    Time frame: 2 years

  5. Any revascularization

    Any revascularization (PCI or CABG)

    Time frame: 2 years

  6. Target lesion revascularization

    Clinically indicated and non-clinically indicated target lesion revascularization

    Time frame: 2 years

  7. Clinically indicated target vessel revascularization

    Clinically indicated and non-clinically indicated target vessel revascularization

    Time frame: 2 years

  8. Definite stent thrombosis

    Academic Research Consortium definite stent thrombosis

    Time frame: 2 years

  9. Definite or probable stent thrombosis

    Academic Research Consortium definite or probable stent thrombosis

    Time frame: 2 years

  10. Bleeding Academic Research Consortium 3 or 5 major bleeding events

    BARC 3 or 5 major bleeding complications

    Time frame: 2 years

  11. Bleeding Academic Research Consortium ≥2 major bleeding events

    BARC ≥2 major bleeding complications

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Zurich University Hospital
    Zurich, Canton of Zurich, Switzerland
    Recruiting
    • Rahel Kesterke, RN · Contact
    • Barbara Stähli, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will be shared upon reasonable request to the principal investigator after publication of the study primary and secondary endpoints.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After publication of the study primary and secondary endpoints.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2022
First posted
Dec 14, 2022
StartActual
Apr 26, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2032
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05650411
Lead sponsor
IGLESIAS Juan Fernando
Collaborators
University of Bern
Responsible party
IGLESIAS Juan Fernando (MD, University Hospital, Geneva) — Sponsor-investigator
First posted
Dec 14, 2022
Start date
Apr 26, 2026
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2032 (estimated)
Last update
May 4, 2026

Study contacts

Maëlle Achard, RN
Contact
maelle.achard@hcuge.ch
+41795533553
Juan F. Iglesias, MD
principal investigator · Geneva University Hospitals, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion